India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S.: sources

India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with

http://in.reuters.com/article/2014/04/09/us-ranbaxy-sunpharma-idINBREA380TN20140409

YOU ARE BEING REDIRECTED TO THE ARTICLE
. . .
× CLOSE

PROCESSING